Inhibition of FLT3 phosphorylation versus tandutinib plasma concentration in assessable patients with FLT3-ITD mutations by dose level and time point
Patient no., treatment . | Tandutinib plasma concentration, ng/mL . | FLT3 inhibition . |
|---|---|---|
| 52 | ||
| 300 mg twice daily | ||
| Day 1, predose | BLQ | NA |
| Day 1, 2 h | 2.7 | No |
| Day 1, 8 h | 30.7 | Yes |
| Day 3 | 13.5 | No |
| Day 10 | 345.8 | Yes |
| 73 | ||
| 525 mg twice daily | ||
| Day 1, predose | BLQ | NA |
| Day 1, 2 h | 218.6 | Yes |
| Day 1, 8 h | 177.1 | Yes |
| Day 3 | 128.3 | Yes |
| 74 | ||
| 525 mg twice daily | ||
| Day 1, predose | BLQ | NA |
| Day 1, 2 h | 139 | Yes |
| Day 1, 8 h | 25.2 | No |
| Day 3 | 87.3 | No |
Patient no., treatment . | Tandutinib plasma concentration, ng/mL . | FLT3 inhibition . |
|---|---|---|
| 52 | ||
| 300 mg twice daily | ||
| Day 1, predose | BLQ | NA |
| Day 1, 2 h | 2.7 | No |
| Day 1, 8 h | 30.7 | Yes |
| Day 3 | 13.5 | No |
| Day 10 | 345.8 | Yes |
| 73 | ||
| 525 mg twice daily | ||
| Day 1, predose | BLQ | NA |
| Day 1, 2 h | 218.6 | Yes |
| Day 1, 8 h | 177.1 | Yes |
| Day 3 | 128.3 | Yes |
| 74 | ||
| 525 mg twice daily | ||
| Day 1, predose | BLQ | NA |
| Day 1, 2 h | 139 | Yes |
| Day 1, 8 h | 25.2 | No |
| Day 3 | 87.3 | No |
BLQ indicates below limit of quantitation; NA, not applicable.